Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update.
Covered in this story
Call it yourself
No calls on $ANAB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Anaptysbio Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.